Metagenomi Therapeutics MGX Ratios (2023-2026)

NASDAQ MGX
$1.20 -0.04 (-3.23%)
At close: Aug 20, 2026 · 4:00 PM EDT
Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin (Quarter) -160.98%-98.00%-150.56%-133.62%-225.36%-64.66%-181.34%-255.94%-604.34%-233.34%-238.21%-575.15%-1,846.88%
EBIT Margin (Quarter) -207.21%-158.45%-181.15%-162.88%-260.17%-84.28%-194.40%-214.51%-674.10%-246.53%-263.76%-623.04%-1,970.11%
EBITDA Margin (Quarter) -207.21%-158.45%-181.15%-162.88%-260.17%-84.28%-194.40%-214.51%-674.10%-246.53%-263.76%-623.04%-1,970.11%
Operating Margin (Quarter) -207.21%-158.45%-181.15%-162.88%-260.17%-84.28%-194.40%-214.51%-674.10%-246.53%-263.76%-623.04%-1,970.11%
Net Margin (Quarter) -186.36%-114.74%-160.32%-155.61%-225.36%-53.67%-163.04%-243.37%-606.71%-233.85%-235.51%-576.02%-1,847.68%
FCF Margin (Quarter) -258.98%-268.90%-210.22%-106.08%-271.24%-134.84%-246.05%-276.78%-560.46%-251.12%-246.30%-604.22%-1,706.65%
Efficiency
Assets Average (Quarter) 390.12M400.65M372.13M341.47M311.23M285.07M260.11M234.52M209.03M185.33M
Asset Utilization Ratio (Quarter) 0.120.140.150.150.150.120.120.110.11
Leverage & Solvency
Interest Coverage Ratio (Quarter) -0.42-7.47-4.30-0.31-9.66-8.69-0.01M-0.02M-219.53-221.33
Times Interest Earned (Quarter) -0.42-7.47-4.30-0.31-9.66-8.69-0.01M-0.02M-219.53-221.33
Valuation
Enterprise Value (Quarter) -95.67M-51.65M-101.90M-271.18M-327.40M-299.92M-274.59M-248.31M-225.97M-204.99M-184.11M-160.80M-140.16M-120.66M
Return Ratios
Return on Sales (Quarter) -0.01%-0.01%-0.02%-0.02%-0.02%-0.01%-0.02%-0.02%-0.06%-0.02%-0.02%-0.01%-0.18%
Return on Capital Employed (Quarter) -28.05%-25.44%-27.10%-29.23%-32.32%-36.46%-40.03%-45.38%-49.74%-63.77%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%